Show simple item record

Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110

dc.contributor.authorMorise, M.
dc.contributor.authorAndric, Z.
dc.contributor.authorGeater, S.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorMocci, S.
dc.contributor.authorMcCleland, M.
dc.contributor.authorZou, W.
dc.contributor.authorEnquist, I.
dc.contributor.authorKomatsubara, K.
dc.contributor.authorKuriki, H.
dc.contributor.authorDeng, Y.
dc.contributor.authorHerbst, R. S.
dc.contributor.authorDe Marinis, F.
dc.contributor.authorGiaccone, G.
dc.contributor.authorStahel, R.
dc.contributor.authorReinmuth, N.
dc.contributor.authorVergnenegre, A.
dc.contributor.authorBarrios, C. H.
dc.contributor.authorFelip, E.
dc.contributor.authorJassem, J.
dc.contributor.authorSpigel, D.
dc.date.accessioned2021-03-02T16:19:24Z
dc.date.available2021-03-02T16:19:24Z
dc.identifier.citationHerbst R. S. , De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., et al., "Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110", SWISS MEDICAL WEEKLY, 2020
dc.identifier.issn1424-7860
dc.identifier.othervv_1032021
dc.identifier.otherav_82abf7d1-8d49-4790-8cc7-858f5d725023
dc.identifier.urihttp://hdl.handle.net/20.500.12627/2857
dc.language.isoeng
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.titleClinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110
dc.typeMakale
dc.relation.journalSWISS MEDICAL WEEKLY
dc.contributor.departmentYale University , ,
dc.contributor.firstauthorID2370972


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record